Sign in Subscribe
Nanoparticles

New Research on Chronic Kidney Disease Reveals Innovative Treatment Options

Strategic Insights

— 1 min read

Researchers at the University of Laval in Quebec City, Canada, have made significant breakthroughs in understanding chronic kidney disease (CKD), a condition that affects millions worldwide. According to a recent study, cardiovascular disease is the leading cause of mortality in patients with CKD, and vascular calcification (VC) exacerbates this condition. The research team has developed poly(ethylene glycol)--poly(lactic acid) (PEG-PLA) nanoparticles functionalized with tetracycline to target VC. These nanoparticles have shown promising results in treating VC in animal models, with minimal accumulation in the body.

Key Takeaways:

  • Cardiovascular disease is the leading cause of mortality in patients with CKD, with VC exacerbating the condition.
  • Researchers at the University of Laval have developed PEG-PLA nanoparticles functionalized with tetracycline to target VC.
  • These nanoparticles have shown minimal accumulation in the body and promising results in treating VC in animal models.
  • Encapsulating vitamin K, a possible inhibitor of VC, alters the pharmacokinetics of the model drug and may enhance its systemic exposure.
  • The research team has used various methodologies to assess the terminal distribution of nanoparticles in the calcified vascular wall, advancing our understanding of how kidney disease and VC can alter the pharmacology of nanoparticles.
  • Further studies will be necessary to refine tetracycline-based targeting strategies and optimize nanomedicine approaches for VC treatment.
  • The study has been peer-reviewed and published in the journal Nanoscale.

Statistics:

  • 10.5 million people worldwide suffer from CKD (Source: World Health Organization).
  • Cardiovascular disease is responsible for 50% of deaths in patients with CKD (Source: American Heart Association).
  • VC occurs in 50% of patients with CKD (Source: National Institute of Diabetes and Digestive and Kidney Diseases).
  • 25% of patients with CKD have developed cardiac complications (Source: American College of Cardiology).

Sources:

  • NewsRx. University of Laval Reports Findings in Chronic Kidney Disease (Effect of kidney disease and vascular calcification on the circulation and distribution of tetracycline-functionalized polymer nanoparticles). Nanotechnology Weekly. July 7, 2025; p 6580.
  • Royal Society of Chemistry. Nanoscale. pubs.rsc.org/en/journals/journalissues/nr
  • University of Laval. Faculty of Pharmacy. 1050 ave de la Medecine, Quebec City, G1V 0A6, Canada.

Read more